Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology innovation company, today announced that it will discontinue the Phase 3 UNITY study of efgartigimod subcutaneous ...
Invertebrate research bias in ecology is measurable and worsening: a new audit of 1.38 million papers across 612 journals by ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results